Samsung Biologics has recently won the cell line patent invalidation trial filed in China against the Swiss multinational biotech company, Lonza, it was learned.In January, the company filed a trial for invalidation of cell line-related patents with China's National Intellectual Property Administrat
Samsung Bioepis has won a marketing permit for its macular degeneration treatment Byooviz, a biosimilar of Lucentis (ingredient: ranibizumab), from the European Commission.The company had waited for two months since the Committee for Medicinal Products for Human Use (CHMP) under European Medicines A
ImmuneMed said it would present the results of a Covid-19 treatment study in Indonesia in the fourth quarter.The company plans to apply for a phase 3 trial and emergency use approval apparently in Indonesia.However, in Korea, the company is believed to have discontinued a local Covid-19 treatment tr
Samsung Biologics denied speculations by an analyst that it may expand its business to new drug development through an open innovation method.Kim Hyeong-soo, an analyst at Hanwha Investment & Securities, predicted in a report Wednesday that Samsung Biologics' investment of 49.5 billion won ($42.3 mi
Genexine is soon to conduct a phase 2/3 trial of Covid-19 vaccine candidate GX-19N in Indonesia but has yet to register the study on ClinicalTrials.gov, a registry of global clinical trials. The company obtained Indonesian approval for the study in early July.The South Korean biotech company said th
Scioto Biosciences, a subsidiary of immuno-oncology firm Genome & Company, said it has completed the first administering of SB-121, a microbiome treatment for autism, on patients in the United States.“We moved a step forward to developing the first-in-class drug for autism treatment,” Genome & Compa
Korean companies are actively studying how to use mRNA technology not only to fight Covid-19 but to treat cancer.In other countries, researchers are conducting clinical trials of a combination of mRNA vaccine and immunotherapy. Moderna teamed up with Merck, and CureVac/BioN Tech with Roche/Genetech,
Many parents are seeking newborn screening to identify the baby’s rare genetic disorders.However, a local newborn screening service is suspected of going beyond the legal line to run unauthorized genetic testing without the knowledge of parents and the doctor, industry sources said.During the proces
Bridge Biotherapeutics said Friday that it recorded sales of 1.3 billion won ($11.3 million) and a net loss of 11.7 billion won based on consolidated financial statements in the first half of this year. The new drug developer added that it spent 9 billion won on research and development in the first
For Korea to become a global vaccine manufacturing hub, it needs to secure high value-added vaccine technologies and production capacity based on intensive public-private partnership, investment, and a mid-to-long-term strategy, a biotech industry report said.Korea Biotechnology Industry Organizatio
The Japanese government led by Prime Minister Yoshihide Suga recently announced that it would tighten the fiscal policy, promoting biosimilar-friendly measures.Korean biosimilar manufacturers operating in Japan, such as Celltrion Healthcare and Dong-A ST, are likely to benefit from Japan’s new econo
Celltrion said Wednesday that it has applied for changing the permission of its Covid-19 treatment, Regkirona (ingredient: regdanvimab), based on the interim results of a global phase 3 clinical trial.Through the new application, the company seeks to change the conditional approval to an official on
JW Bioscience has proved the patentability of its source technology that can diagnose sepsis at an early phase in China, following the U.S. and Japan.The company, a subsidiary of JW Life Science, said Wednesday that it won a Chinese patent for its original technology to make an early diagnosis of se
Celltrion Healthcare's biosimilar drug Herzuma (ingredient: trastuzumab) for breast and gastric cancer had more than 51 percent of the market share in Japan in June, overtaking the original therapies sold in the country.The company said Herzuma took the top place in Japan with the reliability proved
Korean developers of Covid-19 vaccines are struggling to purchase licensed vaccines, which can be compared to their candidate vaccines in comparative immunogenicity trials.Industry officials said securing comparative vaccines has become a new stumbling block to developing a homegrown Covid-19 vaccin
Theragen Bio said Monday that it has won a patent for an algorithm that enables selecting customized chemotherapy, identifying drug mechanisms, and predicting cancer risk based on gene analysis. The technology extracts specific signature genes that use artificial intelligence and big data to make pr
Technology experts from the Russian Direct Investment Fund (RDIF) recently visited Prestige Biopharma, a Korean contract manufacturing organization, to observe the pilot production of Sputnik Light, a Covid-19 vaccine developed in Russia.Industry watchers are paying attention to whether the Korean c
Abclon said Friday that it has signed a memorandum of understanding with Abtis to co-develop a new antibody-drug conjugate (ADC).By combining Abclon’s ability to discover antibodies and Abtis’s ADC platform technology, the agreement aims to develop more safe and effective ADC than existing treatment
Alteogen released the phase 1 clinical trial results of antibody-drug conjugate (ADC) to treat breast cancer.As the company confirmed the safety and efficacy of the drug candidate in the phase 1 study, it will diversify indications in the phase 2 study and seek an opportunity to license it out.In a
Shares of KangStem Biotech fell after the company’s abrupt announcement of a plan for a rights issue to finance its clinical trials and operations. The company said it planned to apply for a clinical trial of its main pipeline this month.On Monday, KangStem Biotech said it would sell stocks to raise